Washington, DC (PRWEB) October 4, 2007
Cardiocore, a premier centralized cardiac safety testing laboratory, announced the launch of its newest office in San Francisco, California. The West Coast operation includes medical, project management, data management and site provisioning personnel, increasing Cardiocore's electrocardiography and echocardiography processing capacity.
"We are delighted to formally launch our Bay Area office," said Cardiocore CEO, Jennifer Cotteleer. She explained, "Extreme customer satisfaction has made Cardiocore the fastest growing cardiac core lab in the world. As we engage with more clients and sites on the West Coast, throughout Asia and in Australia, we are committed to continue providing the high-touch professional care our customers have come to rely upon."
The South San Francisco facility is managed by Polina Voloshko, MD, Cardiocore's Vice President of Medical Operations. Previously, Dr. Voloshko was the Vice President of Cardiovascular Clinical Services with the esteemed Ischemia Research and Education Foundation and their spin-off core lab, Gentiae. With a long history of serving Bay Area biotechnology sponsors, Dr. Voloshko and her clinical team have developed deep expertise in testing both cardiac safety and efficacy. That experience spans many therapeutic areas including oncology, and includes various testing methods such as ECG analysis, ECHO analysis and Holter monitoring.
Dr. Voloshko is also uniquely qualified to coordinate research activities with sites and sponsors in Eastern Europe and Asia. Her cardiology career began with Magna Cum Laude honors at the First St. Petersburg Medical School in Russia, and included service as the Chief of Cardiology at the Riga City Hospital in Latvia.
"Cardiocore's global reach now spans wider than any other core lab," Dr. Voloshko noted, adding, "The West Coast facility compliments Cardiocore's U.S. headquarters in Washington, DC, and European operation in London, U.K. Cardiocore's global footprint now spans eight time zones fortifying its 24/7/365 customer and site support services."
Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 14 years. Services include centralized electrocardiographic (ECG) analysis, Holter monitoring, echocardiography, statistical analysis and consulting services such as protocol design. The company is experienced in design and implementation of Thorough QT Trials and cardiac safety and efficacy testing in Phase I, II and III clinical trials. These services are supported by the company's CardioCorrect® system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England.